Drugs / EGFR CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03152435 | Jun 2017 → Sep 2019 | colorectal cancer, susceptibility to, 4 | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03152435 ↗ |
| Action | Deplete | “in order to tells the T cells to recognize their target tumor cells and potentially kill them” NCT03152435 ↗ |
| Modality | Cell therapy | “The CART cells will then be expanded in vitro and then administered to subjects.” NCT03152435 ↗ |
| Target | EGFR | “chimeric antigen receptor EGFR (EGFR CART) cells” NCT03152435 ↗ |